VIR BIOTECHNOLOGY INC. - COMMON STOCK

GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab

28 7 2021 06:20:10 提供 Nasdaq GlobeNewswire

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021

22 7 2021 16:05:01 提供 Nasdaq GlobeNewswire

Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

15 7 2021 08:30:00 提供 Nasdaq GlobeNewswire

Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021

25 6 2021 08:50:00 提供 Nasdaq GlobeNewswire

GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab

21 6 2021 07:06:20 提供 Nasdaq GlobeNewswire

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021

14 6 2021 08:00:01 提供 Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference

02 6 2021 16:05:00 提供 Nasdaq GlobeNewswire

GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients

26 5 2021 18:57:50 提供 Nasdaq GlobeNewswire

CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19

21 5 2021 09:26:11 提供 Nasdaq GlobeNewswire

EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19

21 5 2021 08:04:54 提供 Nasdaq GlobeNewswire

Vir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details

10 5 2021 16:05:00 提供 Nasdaq GlobeNewswire

GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19

07 5 2021 05:53:33 提供 Nasdaq GlobeNewswire

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results

06 5 2021 16:05:02 提供 Nasdaq GlobeNewswire

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021

22 4 2021 16:01:00 提供 Nasdaq GlobeNewswire

Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

21 4 2021 08:00:01 提供 Nasdaq GlobeNewswire

GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19

15 4 2021 09:50:56 提供 Nasdaq GlobeNewswire

Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells

08 4 2021 08:30:00 提供 Nasdaq GlobeNewswire

Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference

06 4 2021 16:01:00 提供 Nasdaq GlobeNewswire

Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant

05 4 2021 08:00:00 提供 Nasdaq GlobeNewswire

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

29 3 2021 08:30:00 提供 Nasdaq GlobeNewswire